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CD4+Foxp3+ regulatoryT cells (Tregs) have a fundamental role in maintaining immune bal-
ance by preventing autoreactivity and immune-mediated pathology. However this role of
Tregs extends to suppression of anti-tumor immune responses and remains a major obsta-
cle in the development of anti-cancer vaccines and immunotherapies. This feature of Treg
activity is exacerbated by the discovery that Treg frequencies are not only elevated in the
blood of cancer patients, but are also significantly enriched within tumors in comparison to
other sites. These observations have sparked off the quest to understand the processes
through which Tregs become elevated in cancer-bearing hosts and to identify the specific
mechanisms leading to their accumulation within the tumor microenvironment. This man-
uscript reviews the evidence for specific mechanisms of intra-tumoral Treg enrichment
and will discuss how this information may be utilized for the purpose of manipulating the
balance of tumor-infiltrating T cells in favor of anti-tumor effector cells.
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WHAT ARE Tregs?
Regulatory T cells (Tregs) are suppressor cells that are necessary
for maintaining immune homeostasis and immunological toler-
ance to self and which play a key role in limiting excessive and
harmful immune responses (1). Several different types of suppres-
sor T cells have been described including cells within both CD4+
and CD8+ populations (2). The most prominent of these express
both CD4 and Foxp3 and can arise either in the thymus or in the
periphery (1). A recent correspondence in Nature Immunology rec-
ommended the adoption of new nomenclature for Tregs (3). The
authors suggested that thymus-derived Treg cells be called tTreg
(rather than nTreg) to denote those that are thymus-derived and
pTreg for those that differentiate in the periphery [therefore replac-
ing the terms i(induced)Treg and a(adaptive)Treg]. This review
will, as far as possible, adopt the recently recommended nomen-
clature. In addition the term Treg will only be used to describe cells
where suppressor activity has been demonstrated either in vivo or
in vitro and where suppressor function has not been confirmed,
the cells will be termed Foxp3+CD4+ T cells.
PROMOTION OF TUMOR PROGRESSION BY Tregs
There is an emerging consensus that effective anti-tumor immu-
nity is characterized by a Thelper1 (Th1)/CD8
+ T cell response
(4). This type of response however, is susceptible to suppression
by Tregs and several studies using mouse models have shown that
partial or complete removal of this inhibitory influence uncovers
anti-tumor immune responses capable of preventing tumor devel-
opment and limiting tumor progression (5–7). Approaches aimed
at modulating Foxp3+ T cell frequencies in patients with cancer
have been shown to enhance vaccine-induced anti-tumor immune
responses and even boost endogenous responses (8–11). These
exciting findings underpin the importance of fully understanding
the role of Tregs in cancer so that these cells can be manipulated in
order to optimize cancer immunotherapy.
MECHANISMS OF Foxp3+ T CELL ENRICHMENT WITHIN
TUMORS
Studies have shown that progressing mouse and human tumors
can be associated with enhanced Tregs activity and escalating
immune suppression (12, 13). Indeed Foxp3+ T cells manage
to successfully pervade, and often dominate the tumor-specific
immune response; Foxp3+ to Foxp3− T cell ratios in the range
0.5–1:1 have been described in some tumors (12, 14, 15). A few
theories have been proposed to explain how Foxp3+ T cells become
enriched in tumors and in the peripheral blood of tumor-bearing
hosts. There may be preferential migration of Foxp3+ T cells
to tumors in response to chemokines expressed by tumor cells
and stroma. Foxp3+ T cells, preferentially attracted to the tumor
microenvironment may use the same or additional cues to aid their
retention within the tumor mass. In addition, tumor establish-
ment may trigger production of a cocktail of factors that support
increased Foxp3+ T cell proliferation and/or the conversion of
conventional Foxp3−CD4+ T cells into Foxp3+ cells. Various lines
of supporting evidence exist for these mechanisms of Foxp3+ T
cell enrichment in tumors and will be discussed in this review.
CHEMOKINE-MEDIATED RECRUITMENT OF Foxp3+ T CELLS
INTO TUMORS
Migration of cells into peripheral tissues and sites of inflamma-
tion depends on their expression of various chemokine receptors,
selectins (and selectin ligands), and integrins. Generally, effector-
like inflammation-seeking T cells (including Tregs) express inflam-
matory chemokine receptors and adhesion molecules that enhance
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their capacity to migrate to inflamed tissues (16–24). Different
tumors are characterized by unique albeit overlapping chemokine
signatures. Tumor cells and surrounding stromal cells can express
these chemokines, which serve to facilitate migration and accu-
mulation of various leukocytes in the tumor (25–27). While some
of these leukocytic infiltrates comprise macrophages (28) and
myeloid derived suppressor cells (MDSCs) (29) which promote
tumor progression and metastasis, a high frequency of infiltrat-
ing CD3+ T cells often correlates with improved clinical outcome,
e.g., in ovarian and colorectal cancer (CRC) (30, 31). Whether or
not the degree of CD3+ T cell infiltrate correlates with strong
anti-tumor immunity may also depend on the frequency and
suppressive capacity of tumor-infiltrating Tregs. Consequently,
increased infiltration of Foxp3+ T cells is often associated with
a poor prognosis and accelerated tumor progression (32).
INFLAMMATORY CHEMOKINES AND THEIR RECEPTORS
CCR4
CCR4 has been shown to be expressed on a greater proportion
of Tregs than conventional T cells and to be important for guiding
Tregs to sites of inflammation (24, 33). Several studies indicate that
the tumor-expressed chemokines CCL22 and CCL17, which are
ligands for CCR4, play a role in the recruitment and enrichment
of Tregs. A study by Curiel and colleagues, clearly demonstrated a
major role for CCL22 in recruitment of CCR4+ Tregs into human
ovarian carcinomas (13). CCL22 alone, or in combination with
CCL17, has been implicated in Treg recruitment to human breast
(34, 35) and prostate (36) cancers. Increased levels of CCL17
and/or CCL22 are also associated with higher frequencies of
CD4+Foxp3+ T cells in cerebral spinal fluid of patients with lym-
phomatous and carcinomatous meningitis (37), gastric (38), and
esophageal squamous cell carcinomas (39). Using mouse models,
several approaches, including the use of specific antibodies, antag-
onists, or siRNA, have been used to block the CCL22/CCL17 –
CCR4 axis, resulting in reduction in Treg frequencies and a
concomitant increase in anti-tumor activity (40–42).
CCR5
Disruption of CCR5/CCL5 signaling has also been shown in
mouse models to impair intra-tumoral Treg accumulation and
slow tumor progression (43). Similarly, CCL5 levels correlate with
increased Treg frequencies and impaired CD8+ T cell responses in
human colon cancer (44). Further evidence for CCR5-dependent
Treg enrichment comes from a study exploring the potential
mechanisms through which MDSCs inhibit anti-tumor immu-
nity. MDSCs infiltrating mouse RMA-S lymphomas were shown
to increase the levels of CCL3, CCL4, and CCL5, which in
turn enhanced the recruitment of CD4+Foxp3+ T cells via
CCR5 (45). CCR5 deficiency (demonstrated by use of CCR5−/−
mice) or CCL5 blockade (using Met-RANTES) led to diminished
CD4+Foxp3+ T cells numbers and slower tumor growth (45).
However, apart from its ability to attract CD4+Foxp3+ T cells
to tumors, the pivotal role for CCR5 in mediating recruitment
and activation of conventional T cells dictates that CCR5 is also
important for achieving strong anti-tumor immune responses and
regression of established tumors (46–49). Thus, although the find-
ings of some mouse models indicate that the CCR5 axis can be
targeted to reduce Treg accumulation, the general utility of this
approach is likely to be limited by the potential for concurrent
effects on anti-tumor effector cells.
CXCR3
A similar situation applies to the chemokine receptor CXCR3.
Intra-tumoral accumulation of CXCR3+Foxp3+ T cells has
been reported in human ovarian, colorectal, and hepatocellu-
lar carcinomas (50, 51). However, like CCR5, CXCR3 is abun-
dantly expressed on activated cells, binding the IFN-γ-induced
chemokines, CXCL9, CXCL10, and CXCL11. Indeed, homing and
migration of activated effector cells (CTL, NK, NKT, and T helper)
is highly dependent on CXCL9/CXCL10/CXCL11 – CXCR3 signal-
ing thereby limiting the utility of this pathway for targeted preven-
tion of Treg recruitment. CXCR3 and CCR5 are often co-expressed
by effector T cells. In a study of human colorectal carcinomas
expressing CXCL10 and CCL5, the CD8+IFNγ+ T cell infiltrate
comprised predominantly CXCR3+CCR5+ cells (52), concurrent
with a favorable prognosis as previously described (30). Similarly,
CXCL9, CXCL10, and CXCL11 expression by sporadic human
renal cell carcinomas was associated with increased frequency of
CXCR3+CCR5+ T cells and a favorable prognosis which was char-
acterized by the absence of recurrences following curative surgery
(53). Furthermore tumor-expressed CXCL9 was shown to be cru-
cial for immune control of murine cutaneous fibrosarcomas (54)
while CXCL11 secretion by genetically modified mouse T cell lym-
phoma cells (EL4) led to increased infiltration of CD8+CXCR3+
T cells and subsequent tumor rejection (55). Considering the body
of evidence highlighting a favorable prognosis for cancers express-
ing these IFN-γ induced chemokines, disruption of the CXCR3
and/or CCR5 pathways to prevent Treg accumulation in tumors is
unlikely to be effective for promoting tumor immunity.
HYPOXIA-INDUCED CHEMOKINES AND THEIR RECEPTORS
CCR10
Hypoxia and angiogenesis are both characteristic features of
advanced solid tumors. Both of these features also serve to mod-
ulate the enrichment of intra-tumoral Tregs expressing CCR10.
CCL28, a chemokine known to be upregulated by hypoxia has
recently been shown to recruit CCR10+ Tregs to mouse ovarian
cancers (56). These CCR10+ Tregs contributed to tumor progres-
sion by secreting vascular endothelial growth factor A (VEGF-A),
thereby promoting angiogenesis. Understanding the nature of the
relationship between VEGF-A and Tregs may prove important.
VEGF-A blockade not only reduced angiogenesis but also has
been shown to reduce the extent of Treg infiltration in mouse
models resulting in enhanced vaccine-induced immune responses
(57). Moreover, treatment of CRC patients with the anti-VEGF-
A monoclonal antibody bevacizumab reversed Treg accumulation
in patients’ blood (58) whilst VEGFR2+CD4+Foxp3+ cells are
reportedly associated with poor prognosis in CRC (59) supporting
the theory that angiogenic factors may be targeted for the pur-
pose of modulating both angiogenesis and the anti-tumor immune
response.
CXCR4
Vascular endothelial growth factor A has also been shown to work
synergistically with CXCL12, a chemokine commonly expressed by
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tumors, to promote tumor angiogenesis (60). In a study of patients
with basal-like breast cancers, infiltration with Foxp3+ cells was
shown, as above, to correlate with tumor hypoxia (61). In this study
however, a preferential accumulation of Foxp3+ cells expressing
CXCR4, the receptor for CXCL12, was observed. The authors fur-
ther showed that accumulation of these CXCR4+Foxp3+ cells
was associated with a poor prognosis. Although CD8+ and
Foxp3−CD4+ T cells can also express CXCR4, there are reports
that CXCL12 preferentially attracts Tregs to human lung ade-
nocarcinomas (62) and advanced cervical cancers (63), thereby
indicating that targeting the CXCR4–CXCL12 axis may repre-
sent a useful means of selectively reducing the intra-tumoral Treg
infiltrate. In support of this, using a mouse model of ovarian can-
cer, Righi and colleagues showed that administration of a specific
CXCR4 antagonist, AMD3100 (64), was associated with several
anti-tumor effects including increased tumor cell death, reduced
dissemination and angiogenesis and better survival of the treated
animals (65). Significantly, the authors also observed a selective
reduction in the recruitment of Foxp3+ T cells in comparison
with CD8+ T cells (65).
The picture that emerges from these reports is that tumors with
high levels of Tregs, recruited in response to hypoxia (via CCR10
and/or CXCR4), are rich in VEGF-A and therefore, serve to drive
neovascularization. Such a pathway implies that angiogenesis and
the recruitment and activity of Tregs work side-by-side, facilitating
tumor growth directly through neovascularization and indirectly
through promoting immune suppression. With this in mind, it
may prove useful to further explore potential synergy between
therapies targeting angiogenesis and those targeting Tregs.
LYMPHOID-ASSOCIATED CHEMOKINES AND THEIR
RECEPTORS
CCR7
The role of CCL21/CCR7 signaling in the recruitment and accu-
mulation of Tregs in tumors has been described in one study using
B16 melanomas engineered to express higher levels of CCL21.
These tumors recruited high numbers of Tregs and progressed
more rapidly compared to tumors expressing normal or lower
CCL21 levels (66). In contrast, other studies indicate that the
CCL21/CCR7 pathway promotes increased tumor control as a
result of increased recruitment of effector immune cells (67).
Furthermore, intra-tumoral expression of CCL21 boosted CTL
responses after DNA vaccination of mice and induced regres-
sion of B16 melanomas (68). In another study, intra-tumoral
delivery of CCL21 inhibited lung cancer growth in mice. Inhi-
bition of tumor growth was associated with reduced frequencies
of Tregs and MDSC but enhanced recruitment of CCR7+Foxp3−
T cells (69). Moreover, a recent study of patients with metasta-
tic CRC indicated that tumor infiltration with CCR7+ T cells
was associated with a more favorable prognosis (70). Given the
plethora of studies highlighting the important role of CCL21
in recruitment of immune effector cells and subsequent tumor
immunity and the paucity of studies to support enhanced
Treg recruitment to the tumor via CCL21/CCR7, it is highly
unlikely that selective targeting of this pathway as a means to
prevent Treg recruitment will be of clinical benefit in cancer
patients.
Whether chemokines lead to the preferential enrichment of
Tregs in tumors is as yet unclear although there is evidence
that Treg recruitment to tumors may be selectively inhibited
through chemokine receptor blockade: the most notable candi-
dates being CCR4, CXCR4, and CCR10. Such strategies may not
however, impinge on the existing pool of tumor-infiltrating Tregs.
Chemokines may perform functions other than to attract Tregs to
tumors. It is highly likely for example, that chemokines, expressed
intra-tumorally, serve to retain Treg cells, perhaps preferentially,
within the tumor mass. If this is the case, selective retention of
Tregs in the tumor microenvironment could significantly influ-
ence their fate compared to that of conventional T cells, with
clear immunosuppressive consequences. Although the key role of
chemokines is to act as chemoattractants, a role for CCL5 in pro-
moting T cell activation has been demonstrated; in these studies
CCL5 was shown to induce signaling events in T cells in antigen-
independent fashion (71, 72). This finding raises the intriguing
possibility that chemokines present within the tumor microen-
vironment may influence T cell activity, including the activity
of Tregs.
INDUCTION OF Tregs IN THE TUMOR MICROENVIRONMENT
The possibility that conversion of conventional T cells into Tregs
represents a mechanism of Treg enrichment in tumors has been
explored. In adoptive transfer experiments, purified CD4+CD25−
T cells transferred into tumor bearing mice have been shown to
convert into Foxp3+CD4+CD25+ cells within the tumor microen-
vironment (73, 74). In studies of patients with melanoma, Four-
cade and colleagues demonstrated that CD4+CD25− T cells and
Foxp3+CD4+ T cells could recognize the same peptide and more-
over, clonotypic analyses of these cells revealed a common T cell
receptor (TCR) Vβ usage (75). These findings are compatible with
the hypothesis that conventional tumor-specific T cells can con-
vert into Tregs. Whilst the potential for conversion of conventional
T cells into Tregs is undoubtedly demonstrated in these types of
studies, the extent to which this contributes to what is a significant
intra-tumoral enrichment of Foxp3+ T cells is unclear. Addressing
this question directly has been hampered by reports that Foxp3 can
be transiently upregulated on activated T cells without necessarily
conferring suppressor functions and a lack of definitive mark-
ers to discriminate tTregs from pTregs. The “best” markers are the
transcription factor, Helios, and the type 1 transmembrane pro-
tein, neuropilin 1 (Nrp1), which, according to some reports, are
expressed mainly by tTregs (76, 77). In the case of renal cell can-
cer patients, the significant increase in Foxp3+ T cells observed
in both untreated and IL-2-treated patients are helios+ suggesting
that tumors drive expansion of tTreg and not pTregs (78). The same
observation has been made in studies of patients with glioblastoma
multiforme (GBM) and parallel studies of orthotopic mouse mod-
els of brain tumors (79). Studies of Nrp1 expression have resulted
in mixed findings where in some mouse tumors Nrp1+Foxp3+ T
cells predominate whereas in others they do not (80, 81). The valid-
ity of both helios and Nrp1 as true discriminators of tTregs versus
pTregs has however been disputed, thus no definitive conclusions
can be drawn from the studies described above (82, 83).
Working on the premise that pTregs and conventional T
cells share the same TCRs, we used a mouse model of
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carcinogen-induced tumors to compare the TCR repertoires of
tumor-infiltrating Foxp3− and Foxp3+CD4+ T cells in order to
determine the extent of TCR overlap between the two popula-
tions following their recovery from the tumor microenvironment
(15). The data clearly indicated that the TCR repertoires of tumor-
infiltrating Foxp3− and Foxp3+CD4+ T cells are distinct, implying
that at least in the case of carcinogen-induced tumors, conver-
sion of conventional T cells is not a significant cause of intra-
tumoral Treg enrichment. This finding was confirmed in a similar
analysis of CD4+Foxp3+ T cells recovered from TRAMP mice in
which prostate cancer is driven by transgenic expression of SV40
large T antigen (84). In this study, thymic development of the
CD4+Foxp3+ T cells was Aire-dependent and the cells appeared
to be specific for a prostate-associated self-antigen. Overall, the
results of this study support enrichment of intra-tumoral tTregs as
the main mechanism of Treg accumulation in tumors rather than
conversion of conventional T cells to pTregs.
Collectively, evidence to support conversion as a major mech-
anism of Treg enrichment in tumors is currently weak. Most of
the direct evidence for a limited role for conversion has how-
ever, come from mouse models. There are reports that human
CD4+Foxp3− cells can convert into CD4+Foxp3+/lo Tregs in vitro
and that the phenotypic characteristics of these cells can resemble
CD4+ T cell sub-populations isolated from tumors (85). Whilst
these data do not provide definitive answers relating to the rela-
tionship between different tumor-infiltrating T cell subpopulation
(such as that gained from TCR clonotyping), it remains possible
that in human cancers, there is some enrichment of pTregs.
SUPERIOR PROLIFERATION OF tTregs WITHIN THE TUMOR
MICROENVIRONMENT
Given the evidence that Foxp3+CD4+ T cells gain an edge in
accessing the tumor microenvironment through a combination
of differential chemokine receptor expression and an increased
capacity to migrate in response to hypoxia-induced chemokines
and VEGF-A, it is reasonable to speculate that migration does con-
tribute to their observed enrichment within the tumor microenvi-
ronment. Higher frequencies of Foxp3+CD4+ T cells are however
also observed in spleen/blood and draining lymph of tumor-
bearing mice and patients with cancer compared to non-tumor-
bearing controls. In carcinogen-induced tumors, enhanced pro-
liferation of CD4+CD25+ T cells has been reported (86). Studies
examining proliferation of intra-tumoral Foxp3+ T cells in brain
tumors imply that the majority of proliferating cells are helios+;
for example in mouse models of glioblastoma, it has been reported
that the majority of tumor-infiltrating Foxp3+ T cells express
helios and are highly proliferative, significantly more so than
helios−Foxp3+ and Foxp3−CD4+ T cells (79). Moreover, if these
highly proliferative CD4+Foxp3+helios+ cells are, as this study
suggests, suppressive within the tumor microenvironment then
the available evidence favors intra-tumoral expansion of tTreg as a
major mechanism of Treg enrichment in tumors.
Why might CD4+Foxp3+ Tregs demonstrate enhanced prolifer-
ation in the tumor microenvironment compared to CD4+Foxp3−
T cells? Evidence suggests that the Treg population contains a
higher number of cells that respond to self-antigens compared
to Tconv cells (87, 88). Thus, in the case of tumors, Tregs may
receive stronger antigen-driven signals than conventional T cells,
promoting their expansion in tumors. Using a mouse model of
melanoma (B16), Ghiringhelli and colleagues showed that tumors
can license dendritic cells (DCs) to promote the proliferation
of Tregs through the production of TGF-β (89). Another study,
also utilizing the B16 tumor cell line showed that plasmacytoid
DCs promoted Treg activation in an indoleamine 2,3-dioxygenase
(IDO)-dependent manner (90). Whilst both studies assessed Treg
activity in tumor-draining lymph nodes, it is possible similar sig-
nals serve to further promote Treg cell proliferation and survival
within the tumor microenvironment. Of note, IDO production
by human monocyte-derived DCs has also been shown to drive
proliferation of highly suppressive CD4+Foxp3+ T cells (91).
In addition, to these pathways, it has recently been shown that
VEGFR+ Tregs, purified from tumor-bearing mice proliferated in
response to VEGF. The same study also demonstrated reduced Treg
frequencies in the peripheral blood of CRC patients treated with
the VEGF-A blocking antibody, bevacuzimab (58).
Any signal that serves to promote Treg activity, also therefore
serves to indirectly suppress the activities of conventional T cells,
one effect of which is to reduce local production of IL-2. Through
expression of high levels of CD25, Tregs may out-compete con-
ventional T cells for the limited supply of IL-2. Thus, within the
tumor microenvironment Tregs may gain superiority by utilizing
the available IL-2 to support their own proliferation and moreover,
to further promote their immunosuppressive capability (92).
Foxp3+ Tregs – THE TIP OF THE ICEBERG
Although most available evidence indicates that the bulk of tumor-
infiltrating Foxp3+ Tregs are tTreg, this does not preclude a signifi-
cant immunosuppressive role for pTreg or indeed Foxp3− cells.
With the possible exception of melanoma, there is a distinct
paucity of publications detailing the phenotypic and functional
characteristics of tumor-infiltrating T cells, particularly tumor-
infiltrating CD4+ T cells. There are however suggestions that
Foxp3+ Tregs, whether pTregs or tTregs, are not the only sup-
pressive CD4+ T cell sub-population found in tumors. Using a
transgenic mouse model of prostate cancer, Donkor et al. showed
that TGF-β-blockade in Foxp3− T cells resulted in heightened
CTL responses and better immune-mediated control of primary
and metastatic tumors (93). In human studies, elevated frequen-
cies of CD4+ T cells expressing latency associated peptide (LAP)
have been observed in blood of CRC patients compared to healthy
controls. Interestingly, many of these did not express Foxp3 but
could suppress proliferation of LAP− cells in a TGF-β-dependent
fashion (94). Moreover the LAP+CD4+ sub-population cells were
also found in colorectal tumors where their proportions within
the CD4+ tumor-infiltrating T cell pool increased with disease
progression (94). Similarly, in a study of patients with hepatocellu-
lar carcinoma, elevated frequencies of intrahepatic CD4+Foxp3−
cells were observed in cancer patients compared to hepatitis C virus
infected individuals with chronic liver disease; these CD4+Foxp3−
T cells expressed IL-10 and were suppressive in vitro (95). Collec-
tively the data thus far, support a major role for the immuno-
suppressive cytokines IL-10 and TGFβ in mediating the suppres-
sive effects of CD4+Foxp3− T cells. Whether Foxp3− suppres-
sor T cells arise through sustained but inadequate activation of
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FIGURE 1 | Are intra-tumoral Foxp3+ tregs simply the tip of the iceberg?
The tumor microenvironment may consist of several subsets of Treg that
serve to suppress the activities of tumor-specific CD4+ and CD8+ T cells. It
is not yet known whether development of pTreg or suppressor activity
within CD4+Foxp3− T population requires the presence of tTreg.
conventional T cells and/or through mechanisms of infectious
tolerance is unknown. It is extremely important however, to deter-
mine whether or not Foxp3+ Tregs are responsible, directly or
indirectly, for driving the acquisition of suppressor functions of
tumor-infiltrating Foxp3−CD4+ T cells. This information will
reveal whether or not modulating Foxp3+ Tregs will be suffi-
cient for overcoming the influence of intra-tumoral suppressor
T cells or whether multiple suppressor T cell subsets will need to
be independently targeted (Figure 1).
IMPLICATIONS FOR CANCER IMMUNOTHERAPY
Strategies aimed at non-specifically targeting pathways of toler-
ance induction have proven extremely informative and potentially
useful methods of cancer immunotherapy. Boosting conventional
T cell activity through use of CTLA4-blocking antibodies can be
highly effective in the treatment of metastatic melanoma (96,
97). Similarly, early findings with PD-1- or PDL1-blockade has
shown clinical efficacy in melanoma patients without the toxic-
ities observed with anti-CTLA4 antibody treatment (98). These
differential toxic effects of CTLA4- versus PD-1-blockade reflect
the phenotypes described for CTLA4- and PD-1-deficient mice.
Whereas mice lacking CTLA4 exhibit systemic T cell prolifera-
tion (99, 100), those lacking PD-1 exhibit milder symptoms (101).
This difference may be due to the ability of CTLA4 blockade to
induce global T cell activation whereas PD-1 blockade serves to
promote effector T cell responses. Differential effects of CTLA4-
and PD-1-blockade on Tregs are also likely to contribute.
Has our understanding thus far of intra-tumoral Foxp3+
T cell-enrichment identified mechanisms through which their
potential influence on the anti-tumor immune response can be
modulated and used to improve current T cell-orientated treat-
ments (Figure 2)? Blockade of recruitment may be possible;
FIGURE 2 | Pathways ofTreg enrichment in tumors. Studies thus far
indicate that selective migration of Treg and preferential proliferation of tTreg
result in their accumulation in tumors – the main pathways identified thus
far are indicated. Mechanisms promoting both recruitment and proliferation
are indicated in red.
administration of methyl gallate has been shown to inhibit recruit-
ment of CD4+Foxp3+ cells through modulating expression of
CCR4 whilst AMD3100 can antagonize the CXCR4–CXCL12
interaction (41, 65). VEGF-A blockade may also reduce the num-
bers of tumor-infiltrating Tregs through effects on both recruit-
ment (57, 80) and proliferation (58). Moreover, this approach
may also serve to enhance homing of anti-tumor T cells, pos-
sibly due the effects of its blockade on normalization of tumor
blood vessels (102, 103). It may also be the case that targeting
blood vessels can alter the composition of the intra-tumoral T cell
pool. Recently we found that carcinogen-induced tumors were
controlled in a proportion of mice in which Tregs had been largely
ablated. The tumors of these mice, unlike progressing tumors, were
distinguished by the presence of high endothelial venules (HEV);
specialized blood vessels normally found only in lymph nodes that
when present in tumors facilitated entry of anti-tumor effector
cells (5). Thus, disabling Tregs can, directly or indirectly, impact
on blood vessel differentiation, promoting access of anti-tumor
T cells.
As well as VEGF-A, IDO has been implicated in both the
recruitment and activation of Tregs, underpinning the potential
for targeting these molecules for modulating Treg numbers within
tumors (57, 80, 104) (Figure 2). Thus, inhibition of IDO, shown
to be successful in promoting tumor-immunity in many mouse
models, may prove a useful therapeutic target (105).
The enhanced proliferative activity of CD4+Foxp3+ T cells can
also be exploited as a means of targeting Tregs with chemothera-
peutic drugs such as cyclophosphamide. The findings of a recent
study suggest that modulating Treg numbers in this way can be suc-
cessfully combined with vaccination strategies aimed at inducing
or boosting anti-tumor effector T cells (11). It was demonstrated,
in a phase 2 trial involving patients with renal cell carcinoma,
that a single dose of cyclophosphamide reduced Treg numbers and
promoted immune responses to a peptide-based vaccine. These
immune responses were associated with longer overall survival
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(11). Collectively, the data described herein point to the impor-
tance of exploring immunotherapeutic strategies aimed at modu-
lating Treg numbers, boosting anti-tumor T cell responses through
vaccination and influencing blood vessel differentiation for the
purpose of facilitating access of effective anti-tumor T cells to the
tumor microenvironment.
As discussed above, it appears that in terms of T cell-mediated
immunosuppression in the tumor microenvironment, Foxp3+
Tregs are just one subpopulation of suppressor T cell. It is likely that
the tumor-infiltrating CD4+ T cell pool is highly heterogeneous
comprising both Foxp3+ and Foxp3− suppressor cells. It is not
surprising therefore that even in mouse models whereby Foxp3+
Treg cells can be specifically and almost completely ablated that
effects on tumor growth are often modest and in the majority
of cases, despite the systemic autoreactivity induced by Foxp3+
Treg depletion, tumors continue to grow (5–7). It is important
therefore to determine whether ablation of Foxp3+ T cells also
reduces or removes the immunosuppressive influence of Foxp3−
Tregs. Moreover, the nature of anti-tumor T cell responses is not
completely understood. Whilst it is clear that Th1/CD8+ T cell
responses can exert potent anti-tumor activities, some reports also
suggest that Th17 cells can also participate in limiting tumor pro-
gression (106, 107). As reported recently in a study of patients
with pancreatic cancer, Th17 cells may also represent relevant
targets for suppression by Tregs (108). With these questions in
mind, it is imperative that we continue to characterize tumor-
infiltrating T cell pools with respect to deciphering the origins,
specificities, and phenotypes of both Foxp3+ and Foxp3− Tregs
cells and their targets. Such studies may reveal new means of
disabling intra-tumoral Tregs.
Overall, our current knowledge of Tregs indicates that there is
room for optimism. Preclinical and clinical studies will continue
to use current and new findings to examine both benefits and tox-
icities of combination therapies (e.g., immune modulation, blood
vessel normalization, vaccination) aimed at redressing the balance
between tolerance and immunity within the tumor microenviron-
ment. Modulating Treg numbers and activity is likely to represent
an integral part of this process.
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